Transitional Management: The Use of Oral Contraceptives in Perimenopause

A number of perimenopausal women and their health care providers choose to either decline or prematurely discontinue use of oral contraceptives (OCs), despite the availability of formulations that can prevent pregnancy and address perimenopausal symptoms. This lack of use is due to several factors.

[1]  M. Morgan,et al.  Risk of Ovarian Cancer in Relation to Estrogen and Progestin Dose and Use Characteristics of Oral Contraceptives , 2001 .

[2]  A. Davis.  Triphasic norgestimate/ethinyl estradiol oral contraceptive for the treatment of dysfunctional uterine bleeding∗ , 2000 .

[3]  P. Stubblefield,et al.  Low-dose oral contraceptives and bone mineral density: an evidence-based analysis. , 2000, Contraception.

[4]  Adriane Fugh-Berman,et al.  Herb-drug interactions , 2000, The Lancet.

[5]  G. Redmond,et al.  Use of placebo controls in an oral contraceptive trial: methodological issues and adverse event incidence. , 1999, Contraception.

[6]  K. Michaëlsson,et al.  Oral-contraceptive use and risk of hip fracture: a case-control study , 1999, The Lancet.

[7]  E. Negri,et al.  Oral Contraceptive Use and Risk of Colorectal Cancer , 1998, Epidemiology.

[8]  J. Schlesselman,et al.  Risk of endometrial cancer in relation to use of combined oral contraceptives. A practitioner's guide to meta-analysis. , 1997, Human reproduction.

[9]  M. Creinin,et al.  Laboratory criteria for menopause in women using oral contraceptives. , 1996, Fertility and sterility.

[10]  J. Goldzieher,et al.  When is it safe to switch from oral contraceptives to hormonal replacement therapy? , 1995, Contraception.

[11]  A. Glasier,et al.  Incidence of ovulation in perimenopausal women before and during hormone replacement therapy. , 1995, Contraception.

[12]  S. Shapiro,et al.  A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. , 1994, American journal of epidemiology.

[13]  H. Jick,et al.  Oral Contraceptives and Endometrial Cancer , 1993, Obstetrics and gynecology.

[14]  K. Rosenblatt,et al.  Hormonal content of combined oral contraceptives in relation to the reduced risk of endometrial carcinoma , 1991, International journal of cancer.

[15]  J. Potter,et al.  Large bowel cancer in women in relation to reproductive and hormonal factors: a case-control study. , 1983, Journal of the National Cancer Institute.

[16]  S. Henshaw.  Unintended pregnancy in the United States. , 1998, Family planning perspectives.

[17]  W. Willett,et al.  A prospective study of reproductive factors, oral contraceptive use, and risk of colorectal cancer. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[18]  R. Casper,et al.  The Effect of 20 μg Ethinyl Estradiol/1 mg Norethindrone Acetate (MinestrinTM), a Low‐Dose Oral Contraceptive, on Vaginal Bleeding Patterns, Hot Flashes, and Quality of Life in Symptomatic Perimenopausal Women , 1997 .

[19]  A. Decherney.  Bone-sparing properties of oral contraceptives. , 1996, American journal of obstetrics and gynecology.